Dex2021的个人主页 - 老虎社区

Dex2021

Dex2021

暂无个人介绍

IP属地：未知

162关注

8粉丝

0主题

0勋章

2021-11-23

Like

BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%

2021-10-06

Like and comment thanks :)

抱歉，原内容已删除

2021-11-25

Like

Mastercard shares rose nearly 1% in early trading

2021-04-27

$Tiger Brokers(TIGR)$Shorting timeeeee

2021-10-18

Continue to surge or pullback? Like pls

Valneva SE surged over 30% in premarket trading

2021-07-15

Like and comment

OPEC reportedly reaches compromise on oil production after dispute with UAE

2021-06-28

$Atossa Genetics(ATOS)$Can it break 7.50 ifyes will hit $8.5 and by Friday will be HoD

2021-11-30

Like

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

2021-11-10

Like

Coinbase shares fell more than 11% in premarket trading

2021-06-28

$Marin(MRIN)$Break $7🙌🙌

2021-11-22

Like

抱歉，原内容已删除

2021-07-15

Nice

Microsoft to offer cloud-based version of Windows operating system

2021-06-28

Wow

抱歉，原内容已删除

2021-06-11

Good

抱歉，原内容已删除

2021-06-08

WoH

FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades

2021-06-08

$Vinco Ventures, Inc.(BBIG)$is it going to hit 4.50??

2021-06-08

深刻

抱歉，原内容已删除

2021-04-15

Long term EVvvvv

Electric vehicle stocks were down

2021-06-28

Omggggg

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574151786459188","uuid":"3574151786459188","gmtCreate":1611058005231,"gmtModify":1706620610018,"name":"Dex2021","pinyin":"dex2021","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":162,"tweetSize":19,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.07","exceedPercentage":"93.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.23","exceedPercentage":"80.48%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":609239449,"gmtCreate":1638284786701,"gmtModify":1638284786762,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609239449","repostId":"1190156196","repostType":4,"repost":{"id":"1190156196","kind":"news","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","JNJ":"强生","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1,"symbols_score_info":{"BNTX":0.9,"JNJ":0.9,"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874676749,"gmtCreate":1637771949143,"gmtModify":1637771949251,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874676749","repostId":"1127412420","repostType":4,"repost":{"id":"1127412420","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637766895,"share":"https://www.laohu8.com/m/news/1127412420?lang=&edition=full","pubTime":"2021-11-24 23:14","market":"us","language":"en","title":"Mastercard shares rose nearly 1% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1127412420","media":"Tiger Newspress","summary":"Mastercard shares rose nearly 1% in early trading.\nMastercard has acquired Arcus FI, an alum of the ","content":"<p>Mastercard&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/d4d967747245d09157c86522947b6132\" tg-width=\"874\" tg-height=\"599\" width=\"100%\" height=\"auto\"></p>\n<p>Mastercard&nbsp;has&nbsp;acquired&nbsp;Arcus FI, an alum of the company’s Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across&nbsp;Latin America.</p>\n<p>Arcus helps to enable bill pay and cash-in, cash-out services for some of the biggest billers, retailers, fintechs and traditional financial institutions in the&nbsp;U.S.&nbsp;and&nbsp;Mexico, with expansion into&nbsp;Latin America.</p>\n<p>Arcus Pay Network, has access to the largest retailers and direct connection with many of the largest billers in&nbsp;Mexico.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mastercard shares rose nearly 1% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMastercard shares rose nearly 1% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-24 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mastercard&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/d4d967747245d09157c86522947b6132\" tg-width=\"874\" tg-height=\"599\" width=\"100%\" height=\"auto\"></p>\n<p>Mastercard&nbsp;has&nbsp;acquired&nbsp;Arcus FI, an alum of the company’s Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across&nbsp;Latin America.</p>\n<p>Arcus helps to enable bill pay and cash-in, cash-out services for some of the biggest billers, retailers, fintechs and traditional financial institutions in the&nbsp;U.S.&nbsp;and&nbsp;Mexico, with expansion into&nbsp;Latin America.</p>\n<p>Arcus Pay Network, has access to the largest retailers and direct connection with many of the largest billers in&nbsp;Mexico.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MA":"万事达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127412420","content_text":"Mastercard shares rose nearly 1% in early trading.\nMastercard has acquired Arcus FI, an alum of the company’s Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across Latin America.\nArcus helps to enable bill pay and cash-in, cash-out services for some of the biggest billers, retailers, fintechs and traditional financial institutions in the U.S. and Mexico, with expansion into Latin America.\nArcus Pay Network, has access to the largest retailers and direct connection with many of the largest billers in Mexico.","news_type":1,"symbols_score_info":{"MA":0.9}},"isVote":1,"tweetType":1,"viewCount":1097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875444883,"gmtCreate":1637681598264,"gmtModify":1637681598264,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/875444883","repostId":"1119603099","repostType":2,"repost":{"id":"1119603099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637680476,"share":"https://www.laohu8.com/m/news/1119603099?lang=&edition=full","pubTime":"2021-11-23 23:14","market":"us","language":"en","title":"BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119603099","media":"Tiger Newspress","summary":"BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%.The U.S. government asked","content":"<p>BioNTech&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;7%&nbsp;in&nbsp;early&nbsp;trading&nbsp;and&nbsp;Moderna&nbsp;shares&nbsp;slid&nbsp;3%.<img src=\"https://static.tigerbbs.com/89a99816fada5bf2c2120b3cda678cb6\" tg-width=\"871\" tg-height=\"599\" width=\"100%\" height=\"auto\">The U.S. government asked a federal appeals court to immediately lift a court-ordered stay on a sweeping workplace COVID-19 vaccine rule to avoid \"enormous\" harm to public health, or alternatively to allow a masking-and-testing requirement, according to a court filing.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-23 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;7%&nbsp;in&nbsp;early&nbsp;trading&nbsp;and&nbsp;Moderna&nbsp;shares&nbsp;slid&nbsp;3%.<img src=\"https://static.tigerbbs.com/89a99816fada5bf2c2120b3cda678cb6\" tg-width=\"871\" tg-height=\"599\" width=\"100%\" height=\"auto\">The U.S. government asked a federal appeals court to immediately lift a court-ordered stay on a sweeping workplace COVID-19 vaccine rule to avoid \"enormous\" harm to public health, or alternatively to allow a masking-and-testing requirement, according to a court filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119603099","content_text":"BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%.The U.S. government asked a federal appeals court to immediately lift a court-ordered stay on a sweeping workplace COVID-19 vaccine rule to avoid \"enormous\" harm to public health, or alternatively to allow a masking-and-testing requirement, according to a court filing.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1735,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872750237,"gmtCreate":1637578901154,"gmtModify":1637578901245,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872750237","repostId":"2185826772","repostType":4,"isVote":1,"tweetType":1,"viewCount":1483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847561472,"gmtCreate":1636536237233,"gmtModify":1636536261525,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847561472","repostId":"1121876214","repostType":4,"repost":{"id":"1121876214","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636534820,"share":"https://www.laohu8.com/m/news/1121876214?lang=&edition=full","pubTime":"2021-11-10 17:00","market":"us","language":"en","title":"Coinbase shares fell more than 11% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1121876214","media":"Tiger Newspress","summary":"Coinbase shares fell more than 11% in premarket trading.\n\nThe company’s third-quarter earnings and r","content":"<p>Coinbase&nbsp;shares fell&nbsp;more&nbsp;than 11% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f265de3e67a041cf95019dbd440f8b00\" tg-width=\"897\" tg-height=\"609\" width=\"100%\" height=\"auto\"></p>\n<p>The company’s third-quarter earnings and revenue missed analysts’ expectations amid a slowdown in crypto trading in the third quarter. </p>\n<p>Coinbase&nbsp;revenue of $1.3 billion fell short of analysts’ expectations for $1.6 billion and its earnings per share of $1.62 were below estimates of $1.81.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coinbase shares fell more than 11% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoinbase shares fell more than 11% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-10 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Coinbase&nbsp;shares fell&nbsp;more&nbsp;than 11% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f265de3e67a041cf95019dbd440f8b00\" tg-width=\"897\" tg-height=\"609\" width=\"100%\" height=\"auto\"></p>\n<p>The company’s third-quarter earnings and revenue missed analysts’ expectations amid a slowdown in crypto trading in the third quarter. </p>\n<p>Coinbase&nbsp;revenue of $1.3 billion fell short of analysts’ expectations for $1.6 billion and its earnings per share of $1.62 were below estimates of $1.81.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121876214","content_text":"Coinbase shares fell more than 11% in premarket trading.\n\nThe company’s third-quarter earnings and revenue missed analysts’ expectations amid a slowdown in crypto trading in the third quarter. \nCoinbase revenue of $1.3 billion fell short of analysts’ expectations for $1.6 billion and its earnings per share of $1.62 were below estimates of $1.81.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":1564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850951965,"gmtCreate":1634547474992,"gmtModify":1634547902564,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Continue to surge or pullback? Like pls","listText":"Continue to surge or pullback? Like pls","text":"Continue to surge or pullback? Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850951965","repostId":"1158357604","repostType":4,"repost":{"id":"1158357604","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634544827,"share":"https://www.laohu8.com/m/news/1158357604?lang=&edition=full","pubTime":"2021-10-18 16:13","market":"us","language":"en","title":"Valneva SE surged over 30% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1158357604","media":"Tiger Newspress","summary":"(Oct 18) Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate o","content":"<p>(Oct 18)&nbsp;Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.</p>\n<p><img src=\"https://static.tigerbbs.com/75a47283d41a17f67d8b8e370e3900b7\" tg-width=\"1046\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva SE surged over 30% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva SE surged over 30% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-18 16:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 18)&nbsp;Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.</p>\n<p><img src=\"https://static.tigerbbs.com/75a47283d41a17f67d8b8e370e3900b7\" tg-width=\"1046\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158357604","content_text":"(Oct 18) Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829666470,"gmtCreate":1633500586136,"gmtModify":1633500586245,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like and comment thanks :)","listText":"Like and comment thanks :)","text":"Like and comment thanks :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/829666470","repostId":"1123518290","repostType":4,"isVote":1,"tweetType":1,"viewCount":1950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":144667388,"gmtCreate":1626281538044,"gmtModify":1633928273279,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/144667388","repostId":"1103407312","repostType":4,"repost":{"id":"1103407312","kind":"news","pubTimestamp":1626275222,"share":"https://www.laohu8.com/m/news/1103407312?lang=&edition=full","pubTime":"2021-07-14 23:07","market":"us","language":"en","title":"Microsoft to offer cloud-based version of Windows operating system","url":"https://stock-news.laohu8.com/highlight/detail?id=1103407312","media":"Reuters","summary":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-b","content":"<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.</p>\n<p>Windows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.</p>\n<p>But instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.</p>\n<p>The cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.</p>\n<p>\"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.</p>\n<p>The service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.</p>\n<p>Microsoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.</p>\n<p>Andrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft to offer cloud-based version of Windows operating system</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft to offer cloud-based version of Windows operating system\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader ...</p>\n\n<a href=\"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103407312","content_text":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.\nWindows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.\nBut instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.\nThe cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.\n\"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.\nThe service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.\nMicrosoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.\nAndrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.","news_type":1,"symbols_score_info":{"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144667045,"gmtCreate":1626281506287,"gmtModify":1633928273401,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/144667045","repostId":"1181513394","repostType":4,"repost":{"id":"1181513394","kind":"news","pubTimestamp":1626276027,"share":"https://www.laohu8.com/m/news/1181513394?lang=&edition=full","pubTime":"2021-07-14 23:20","market":"fut","language":"en","title":"OPEC reportedly reaches compromise on oil production after dispute with UAE","url":"https://stock-news.laohu8.com/highlight/detail?id=1181513394","media":"CNBC","summary":"DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived","content":"<div>\n<p>DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived at a deal after a nearly two-week standoff over its future oil production levels, according to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OPEC reportedly reaches compromise on oil production after dispute with UAE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOPEC reportedly reaches compromise on oil production after dispute with UAE\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived at a deal after a nearly two-week standoff over its future oil production levels, according to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"source_url":"https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1181513394","content_text":"DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived at a deal after a nearly two-week standoff over its future oil production levels, according to reports by theWall Street JournalandReuters.\nThe temporary but unprecedented gridlock that began in early July saw the United Arab Emirates reject a coordinated oil production plan for the group spearheaded by its kingpin, Saudi Arabia.\nAbu Dhabi had demanded that its own \"baseline\" for crude production — the maximum volume it's recognized by OPEC as being able to produce — be raised because this figure then determines the size of production cuts and quotas it must follow as per the group's output agreements. Members cut the same percentage from their baseline, so having a higher baseline would allow the UAE a greater production quota.\nThe UAE initially called for its baseline to be raised from 3.2 million barrels a day to 3.8 million barrels a day. According to sources cited by the Wall Street Journal, the compromise reached between Saudi Arabia and its smaller neighbor will raise the UAE's baseline to 3.65 million barrels per day from April 2022. The reports have not been officially confirmed, and OPEC and the Saudi energy ministry did not reply to CNBC requests for comment.\nThe initial agreement supported by most OPEC delegates set out a plan for the group to collectively bring production up to 400,000 barrels of crude per day monthly through to the end of 2022. This would end the remaining limits that were set in the spring of 2020, as economic recovery and growing demand for oil have broughtcrude prices up to their highest level since late 2018.","news_type":1,"symbols_score_info":{"XOM":0.9}},"isVote":1,"tweetType":1,"viewCount":717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150122346,"gmtCreate":1624890383685,"gmtModify":1633947411438,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150122346","repostId":"2146835880","repostType":4,"isVote":1,"tweetType":1,"viewCount":748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150126874,"gmtCreate":1624890354098,"gmtModify":1631885419231,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>Break $7🙌🙌","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>Break $7🙌🙌","text":"$Marin(MRIN)$Break $7🙌🙌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150126874","isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150120807,"gmtCreate":1624890249809,"gmtModify":1631884385156,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Can it break 7.50 ifyes will hit $8.5 and by Friday will be HoD","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Can it break 7.50 ifyes will hit $8.5 and by Friday will be HoD","text":"$Atossa Genetics(ATOS)$Can it break 7.50 ifyes will hit $8.5 and by Friday will be HoD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/150120807","isVote":1,"tweetType":1,"viewCount":406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150977893,"gmtCreate":1624885513012,"gmtModify":1633947534227,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Omggggg","listText":"Omggggg","text":"Omggggg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150977893","repostId":"2146887989","repostType":4,"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188807676,"gmtCreate":1623426801295,"gmtModify":1634033295942,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188807676","repostId":"2142022769","repostType":4,"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114438771,"gmtCreate":1623085692693,"gmtModify":1634037102041,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"WoH","listText":"WoH","text":"WoH","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114438771","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://www.laohu8.com/m/news/1108033863?lang=&edition=full","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":59,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114438129,"gmtCreate":1623085642761,"gmtModify":1631884343365,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BBIG\">$Vinco Ventures, Inc.(BBIG)$</a>is it going to hit 4.50??","listText":"<a href=\"https://laohu8.com/S/BBIG\">$Vinco Ventures, Inc.(BBIG)$</a>is it going to hit 4.50??","text":"$Vinco Ventures, Inc.(BBIG)$is it going to hit 4.50??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114438129","isVote":1,"tweetType":1,"viewCount":57,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114438067,"gmtCreate":1623085590959,"gmtModify":1634037102731,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"深刻","listText":"深刻","text":"深刻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114438067","repostId":"1115898009","repostType":4,"isVote":1,"tweetType":1,"viewCount":626,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":374527476,"gmtCreate":1619462153695,"gmtModify":1634273285253,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Shorting timeeeee","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Shorting timeeeee","text":"$Tiger Brokers(TIGR)$Shorting timeeeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374527476","isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344521296,"gmtCreate":1618416824215,"gmtModify":1634293063011,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Long term EVvvvv","listText":"Long term EVvvvv","text":"Long term EVvvvv","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/344521296","repostId":"1186838018","repostType":4,"repost":{"id":"1186838018","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618413882,"share":"https://www.laohu8.com/m/news/1186838018?lang=&edition=full","pubTime":"2021-04-14 23:24","market":"us","language":"en","title":"Electric vehicle stocks were down","url":"https://stock-news.laohu8.com/highlight/detail?id=1186838018","media":"Tiger Newspress","summary":"(April 14) Electric vehicle stocks were down. Shares of Nio was down  6.62% to $33.13 and Nio was 3.","content":"<p>(April 14)&nbsp;Electric vehicle stocks were down.&nbsp;Shares of Nio&nbsp;was&nbsp;down&nbsp;&nbsp;6.62%&nbsp;to&nbsp;$33.13&nbsp;and&nbsp;Nio&nbsp;was&nbsp;3.14% lower.</p><p><img src=\"https://static.tigerbbs.com/d4dccabfcd5d058051278d972adbce18\" tg-width=\"294\" tg-height=\"166\" referrerpolicy=\"no-referrer\">Xpeng Motors launched the P5 on Wednesday, a sedan with new self-driving features.&nbsp;The P5 is equipped with so-called Lidar to aid Xpeng’s driverless system called XPILOT.&nbsp;Xpeng is hoping to close to gap with Tesla as well as race ahead of other rivals such as Nio and Li Auto.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Electric vehicle stocks were down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElectric vehicle stocks were down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-14 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(April 14)&nbsp;Electric vehicle stocks were down.&nbsp;Shares of Nio&nbsp;was&nbsp;down&nbsp;&nbsp;6.62%&nbsp;to&nbsp;$33.13&nbsp;and&nbsp;Nio&nbsp;was&nbsp;3.14% lower.</p><p><img src=\"https://static.tigerbbs.com/d4dccabfcd5d058051278d972adbce18\" tg-width=\"294\" tg-height=\"166\" referrerpolicy=\"no-referrer\">Xpeng Motors launched the P5 on Wednesday, a sedan with new self-driving features.&nbsp;The P5 is equipped with so-called Lidar to aid Xpeng’s driverless system called XPILOT.&nbsp;Xpeng is hoping to close to gap with Tesla as well as race ahead of other rivals such as Nio and Li Auto.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186838018","content_text":"(April 14) Electric vehicle stocks were down. Shares of Nio was down  6.62% to $33.13 and Nio was 3.14% lower.Xpeng Motors launched the P5 on Wednesday, a sedan with new self-driving features. The P5 is equipped with so-called Lidar to aid Xpeng’s driverless system called XPILOT. Xpeng is hoping to close to gap with Tesla as well as race ahead of other rivals such as Nio and Li Auto.","news_type":1,"symbols_score_info":{"NIO":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":67,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":875444883,"gmtCreate":1637681598264,"gmtModify":1637681598264,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/875444883","repostId":"1119603099","repostType":2,"repost":{"id":"1119603099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637680476,"share":"https://www.laohu8.com/m/news/1119603099?lang=&edition=full","pubTime":"2021-11-23 23:14","market":"us","language":"en","title":"BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119603099","media":"Tiger Newspress","summary":"BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%.The U.S. government asked","content":"<p>BioNTech&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;7%&nbsp;in&nbsp;early&nbsp;trading&nbsp;and&nbsp;Moderna&nbsp;shares&nbsp;slid&nbsp;3%.<img src=\"https://static.tigerbbs.com/89a99816fada5bf2c2120b3cda678cb6\" tg-width=\"871\" tg-height=\"599\" width=\"100%\" height=\"auto\">The U.S. government asked a federal appeals court to immediately lift a court-ordered stay on a sweeping workplace COVID-19 vaccine rule to avoid \"enormous\" harm to public health, or alternatively to allow a masking-and-testing requirement, according to a court filing.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-23 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;7%&nbsp;in&nbsp;early&nbsp;trading&nbsp;and&nbsp;Moderna&nbsp;shares&nbsp;slid&nbsp;3%.<img src=\"https://static.tigerbbs.com/89a99816fada5bf2c2120b3cda678cb6\" tg-width=\"871\" tg-height=\"599\" width=\"100%\" height=\"auto\">The U.S. government asked a federal appeals court to immediately lift a court-ordered stay on a sweeping workplace COVID-19 vaccine rule to avoid \"enormous\" harm to public health, or alternatively to allow a masking-and-testing requirement, according to a court filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119603099","content_text":"BioNTech shares fell nearly 7% in early trading and Moderna shares slid 3%.The U.S. government asked a federal appeals court to immediately lift a court-ordered stay on a sweeping workplace COVID-19 vaccine rule to avoid \"enormous\" harm to public health, or alternatively to allow a masking-and-testing requirement, according to a court filing.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1735,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829666470,"gmtCreate":1633500586136,"gmtModify":1633500586245,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like and comment thanks :)","listText":"Like and comment thanks :)","text":"Like and comment thanks :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/829666470","repostId":"1123518290","repostType":4,"isVote":1,"tweetType":1,"viewCount":1950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874676749,"gmtCreate":1637771949143,"gmtModify":1637771949251,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874676749","repostId":"1127412420","repostType":4,"repost":{"id":"1127412420","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637766895,"share":"https://www.laohu8.com/m/news/1127412420?lang=&edition=full","pubTime":"2021-11-24 23:14","market":"us","language":"en","title":"Mastercard shares rose nearly 1% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1127412420","media":"Tiger Newspress","summary":"Mastercard shares rose nearly 1% in early trading.\nMastercard has acquired Arcus FI, an alum of the ","content":"<p>Mastercard&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/d4d967747245d09157c86522947b6132\" tg-width=\"874\" tg-height=\"599\" width=\"100%\" height=\"auto\"></p>\n<p>Mastercard&nbsp;has&nbsp;acquired&nbsp;Arcus FI, an alum of the company’s Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across&nbsp;Latin America.</p>\n<p>Arcus helps to enable bill pay and cash-in, cash-out services for some of the biggest billers, retailers, fintechs and traditional financial institutions in the&nbsp;U.S.&nbsp;and&nbsp;Mexico, with expansion into&nbsp;Latin America.</p>\n<p>Arcus Pay Network, has access to the largest retailers and direct connection with many of the largest billers in&nbsp;Mexico.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mastercard shares rose nearly 1% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMastercard shares rose nearly 1% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-24 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mastercard&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/d4d967747245d09157c86522947b6132\" tg-width=\"874\" tg-height=\"599\" width=\"100%\" height=\"auto\"></p>\n<p>Mastercard&nbsp;has&nbsp;acquired&nbsp;Arcus FI, an alum of the company’s Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across&nbsp;Latin America.</p>\n<p>Arcus helps to enable bill pay and cash-in, cash-out services for some of the biggest billers, retailers, fintechs and traditional financial institutions in the&nbsp;U.S.&nbsp;and&nbsp;Mexico, with expansion into&nbsp;Latin America.</p>\n<p>Arcus Pay Network, has access to the largest retailers and direct connection with many of the largest billers in&nbsp;Mexico.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MA":"万事达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127412420","content_text":"Mastercard shares rose nearly 1% in early trading.\nMastercard has acquired Arcus FI, an alum of the company’s Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across Latin America.\nArcus helps to enable bill pay and cash-in, cash-out services for some of the biggest billers, retailers, fintechs and traditional financial institutions in the U.S. and Mexico, with expansion into Latin America.\nArcus Pay Network, has access to the largest retailers and direct connection with many of the largest billers in Mexico.","news_type":1,"symbols_score_info":{"MA":0.9}},"isVote":1,"tweetType":1,"viewCount":1097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":374527476,"gmtCreate":1619462153695,"gmtModify":1634273285253,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Shorting timeeeee","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Shorting timeeeee","text":"$Tiger Brokers(TIGR)$Shorting timeeeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374527476","isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":850951965,"gmtCreate":1634547474992,"gmtModify":1634547902564,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Continue to surge or pullback? Like pls","listText":"Continue to surge or pullback? Like pls","text":"Continue to surge or pullback? Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850951965","repostId":"1158357604","repostType":4,"repost":{"id":"1158357604","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634544827,"share":"https://www.laohu8.com/m/news/1158357604?lang=&edition=full","pubTime":"2021-10-18 16:13","market":"us","language":"en","title":"Valneva SE surged over 30% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1158357604","media":"Tiger Newspress","summary":"(Oct 18) Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate o","content":"<p>(Oct 18)&nbsp;Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.</p>\n<p><img src=\"https://static.tigerbbs.com/75a47283d41a17f67d8b8e370e3900b7\" tg-width=\"1046\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva SE surged over 30% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva SE surged over 30% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-18 16:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 18)&nbsp;Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.</p>\n<p><img src=\"https://static.tigerbbs.com/75a47283d41a17f67d8b8e370e3900b7\" tg-width=\"1046\" tg-height=\"564\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158357604","content_text":"(Oct 18) Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":144667045,"gmtCreate":1626281506287,"gmtModify":1633928273401,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/144667045","repostId":"1181513394","repostType":4,"repost":{"id":"1181513394","kind":"news","pubTimestamp":1626276027,"share":"https://www.laohu8.com/m/news/1181513394?lang=&edition=full","pubTime":"2021-07-14 23:20","market":"fut","language":"en","title":"OPEC reportedly reaches compromise on oil production after dispute with UAE","url":"https://stock-news.laohu8.com/highlight/detail?id=1181513394","media":"CNBC","summary":"DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived","content":"<div>\n<p>DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived at a deal after a nearly two-week standoff over its future oil production levels, according to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OPEC reportedly reaches compromise on oil production after dispute with UAE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOPEC reportedly reaches compromise on oil production after dispute with UAE\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived at a deal after a nearly two-week standoff over its future oil production levels, according to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"source_url":"https://www.cnbc.com/2021/07/14/opec-reportedly-reaches-compromise-on-oil-production-after-dispute-with-uae.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1181513394","content_text":"DUBAI, United Arab Emirates — The Organization of Petroleum Exporting Countries on Wednesday arrived at a deal after a nearly two-week standoff over its future oil production levels, according to reports by theWall Street JournalandReuters.\nThe temporary but unprecedented gridlock that began in early July saw the United Arab Emirates reject a coordinated oil production plan for the group spearheaded by its kingpin, Saudi Arabia.\nAbu Dhabi had demanded that its own \"baseline\" for crude production — the maximum volume it's recognized by OPEC as being able to produce — be raised because this figure then determines the size of production cuts and quotas it must follow as per the group's output agreements. Members cut the same percentage from their baseline, so having a higher baseline would allow the UAE a greater production quota.\nThe UAE initially called for its baseline to be raised from 3.2 million barrels a day to 3.8 million barrels a day. According to sources cited by the Wall Street Journal, the compromise reached between Saudi Arabia and its smaller neighbor will raise the UAE's baseline to 3.65 million barrels per day from April 2022. The reports have not been officially confirmed, and OPEC and the Saudi energy ministry did not reply to CNBC requests for comment.\nThe initial agreement supported by most OPEC delegates set out a plan for the group to collectively bring production up to 400,000 barrels of crude per day monthly through to the end of 2022. This would end the remaining limits that were set in the spring of 2020, as economic recovery and growing demand for oil have broughtcrude prices up to their highest level since late 2018.","news_type":1,"symbols_score_info":{"XOM":0.9}},"isVote":1,"tweetType":1,"viewCount":717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150120807,"gmtCreate":1624890249809,"gmtModify":1631884385156,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Can it break 7.50 ifyes will hit $8.5 and by Friday will be HoD","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Can it break 7.50 ifyes will hit $8.5 and by Friday will be HoD","text":"$Atossa Genetics(ATOS)$Can it break 7.50 ifyes will hit $8.5 and by Friday will be HoD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/150120807","isVote":1,"tweetType":1,"viewCount":406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":609239449,"gmtCreate":1638284786701,"gmtModify":1638284786762,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609239449","repostId":"1190156196","repostType":4,"repost":{"id":"1190156196","kind":"news","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","JNJ":"强生","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1,"symbols_score_info":{"BNTX":0.9,"JNJ":0.9,"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847561472,"gmtCreate":1636536237233,"gmtModify":1636536261525,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847561472","repostId":"1121876214","repostType":4,"repost":{"id":"1121876214","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636534820,"share":"https://www.laohu8.com/m/news/1121876214?lang=&edition=full","pubTime":"2021-11-10 17:00","market":"us","language":"en","title":"Coinbase shares fell more than 11% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1121876214","media":"Tiger Newspress","summary":"Coinbase shares fell more than 11% in premarket trading.\n\nThe company’s third-quarter earnings and r","content":"<p>Coinbase&nbsp;shares fell&nbsp;more&nbsp;than 11% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f265de3e67a041cf95019dbd440f8b00\" tg-width=\"897\" tg-height=\"609\" width=\"100%\" height=\"auto\"></p>\n<p>The company’s third-quarter earnings and revenue missed analysts’ expectations amid a slowdown in crypto trading in the third quarter. </p>\n<p>Coinbase&nbsp;revenue of $1.3 billion fell short of analysts’ expectations for $1.6 billion and its earnings per share of $1.62 were below estimates of $1.81.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coinbase shares fell more than 11% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoinbase shares fell more than 11% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-10 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Coinbase&nbsp;shares fell&nbsp;more&nbsp;than 11% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f265de3e67a041cf95019dbd440f8b00\" tg-width=\"897\" tg-height=\"609\" width=\"100%\" height=\"auto\"></p>\n<p>The company’s third-quarter earnings and revenue missed analysts’ expectations amid a slowdown in crypto trading in the third quarter. </p>\n<p>Coinbase&nbsp;revenue of $1.3 billion fell short of analysts’ expectations for $1.6 billion and its earnings per share of $1.62 were below estimates of $1.81.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121876214","content_text":"Coinbase shares fell more than 11% in premarket trading.\n\nThe company’s third-quarter earnings and revenue missed analysts’ expectations amid a slowdown in crypto trading in the third quarter. \nCoinbase revenue of $1.3 billion fell short of analysts’ expectations for $1.6 billion and its earnings per share of $1.62 were below estimates of $1.81.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":1564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":150126874,"gmtCreate":1624890354098,"gmtModify":1631885419231,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>Break $7🙌🙌","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>Break $7🙌🙌","text":"$Marin(MRIN)$Break $7🙌🙌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150126874","isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":872750237,"gmtCreate":1637578901154,"gmtModify":1637578901245,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872750237","repostId":"2185826772","repostType":4,"isVote":1,"tweetType":1,"viewCount":1483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":144667388,"gmtCreate":1626281538044,"gmtModify":1633928273279,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/144667388","repostId":"1103407312","repostType":4,"repost":{"id":"1103407312","kind":"news","pubTimestamp":1626275222,"share":"https://www.laohu8.com/m/news/1103407312?lang=&edition=full","pubTime":"2021-07-14 23:07","market":"us","language":"en","title":"Microsoft to offer cloud-based version of Windows operating system","url":"https://stock-news.laohu8.com/highlight/detail?id=1103407312","media":"Reuters","summary":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-b","content":"<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.</p>\n<p>Windows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.</p>\n<p>But instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.</p>\n<p>The cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.</p>\n<p>\"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.</p>\n<p>The service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.</p>\n<p>Microsoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.</p>\n<p>Andrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft to offer cloud-based version of Windows operating system</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft to offer cloud-based version of Windows operating system\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader ...</p>\n\n<a href=\"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://finance.yahoo.com/news/microsoft-offer-cloud-based-version-150308733.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103407312","content_text":"(Reuters) - Microsoft Corp on Wednesday said it will offer its Windows operating system as a cloud-based service, aiming to make it easier to access business apps that need Windows from a broader range of devices.\nWindows 365, as the service will be called, will roll out on Aug. 2 and will work somewhat like buying a new Windows PC: A business or school will pick how much computing power, memory and storage they would like for an the new machine.\nBut instead of waiting for a physical machine to arrive in the mail, the employee or student will access the operating system in the cloud via an existing PC, a Mac, iPhone, Android phone or Chromebook, as long as it has a web browser compatible with HTML 5, a widely used internet standard.\nThe cloud-based version was created in response to feedback from clients who wanted employees and students to have quicker and easier PC access regardless of physical location.\n\"We define that shift to hybrid work as really being flexibility in how, when and where you work. That's really the pattern that we're seeing develop all across the world as people are starting to experiment,\" said Jared Spataro, corporate vice president for Microsoft 365 software.\nThe service is akin to so-called \"virtual\" and \"remote\" desktops that have been around for decades but which require a sophisticated IT department to set up and manage. Those costs can also be unpredictable because they are based on how much the desktops are used.\nMicrosoft hopes the Windows 365 technology will be easy enough for small-business owners or smaller schools to introduce without a large IT department, with a predictable monthly bill based on the size of each virtual computer.\nAndrew Hewitt, an analyst at Forrester Research, said the move would help Microsoft defend its dominant market share in the face of strong competition from operating systems from Apple Inc and Alphabet's Google that are easier for schools and businesses to manage.","news_type":1,"symbols_score_info":{"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150122346,"gmtCreate":1624890383685,"gmtModify":1633947411438,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150122346","repostId":"2146835880","repostType":4,"isVote":1,"tweetType":1,"viewCount":748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188807676,"gmtCreate":1623426801295,"gmtModify":1634033295942,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188807676","repostId":"2142022769","repostType":4,"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114438771,"gmtCreate":1623085692693,"gmtModify":1634037102041,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"WoH","listText":"WoH","text":"WoH","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114438771","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://www.laohu8.com/m/news/1108033863?lang=&edition=full","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":59,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114438129,"gmtCreate":1623085642761,"gmtModify":1631884343365,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BBIG\">$Vinco Ventures, Inc.(BBIG)$</a>is it going to hit 4.50??","listText":"<a href=\"https://laohu8.com/S/BBIG\">$Vinco Ventures, Inc.(BBIG)$</a>is it going to hit 4.50??","text":"$Vinco Ventures, Inc.(BBIG)$is it going to hit 4.50??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114438129","isVote":1,"tweetType":1,"viewCount":57,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114438067,"gmtCreate":1623085590959,"gmtModify":1634037102731,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"深刻","listText":"深刻","text":"深刻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114438067","repostId":"1115898009","repostType":4,"isVote":1,"tweetType":1,"viewCount":626,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":344521296,"gmtCreate":1618416824215,"gmtModify":1634293063011,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Long term EVvvvv","listText":"Long term EVvvvv","text":"Long term EVvvvv","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/344521296","repostId":"1186838018","repostType":4,"repost":{"id":"1186838018","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618413882,"share":"https://www.laohu8.com/m/news/1186838018?lang=&edition=full","pubTime":"2021-04-14 23:24","market":"us","language":"en","title":"Electric vehicle stocks were down","url":"https://stock-news.laohu8.com/highlight/detail?id=1186838018","media":"Tiger Newspress","summary":"(April 14) Electric vehicle stocks were down. Shares of Nio was down  6.62% to $33.13 and Nio was 3.","content":"<p>(April 14)&nbsp;Electric vehicle stocks were down.&nbsp;Shares of Nio&nbsp;was&nbsp;down&nbsp;&nbsp;6.62%&nbsp;to&nbsp;$33.13&nbsp;and&nbsp;Nio&nbsp;was&nbsp;3.14% lower.</p><p><img src=\"https://static.tigerbbs.com/d4dccabfcd5d058051278d972adbce18\" tg-width=\"294\" tg-height=\"166\" referrerpolicy=\"no-referrer\">Xpeng Motors launched the P5 on Wednesday, a sedan with new self-driving features.&nbsp;The P5 is equipped with so-called Lidar to aid Xpeng’s driverless system called XPILOT.&nbsp;Xpeng is hoping to close to gap with Tesla as well as race ahead of other rivals such as Nio and Li Auto.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Electric vehicle stocks were down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElectric vehicle stocks were down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-14 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(April 14)&nbsp;Electric vehicle stocks were down.&nbsp;Shares of Nio&nbsp;was&nbsp;down&nbsp;&nbsp;6.62%&nbsp;to&nbsp;$33.13&nbsp;and&nbsp;Nio&nbsp;was&nbsp;3.14% lower.</p><p><img src=\"https://static.tigerbbs.com/d4dccabfcd5d058051278d972adbce18\" tg-width=\"294\" tg-height=\"166\" referrerpolicy=\"no-referrer\">Xpeng Motors launched the P5 on Wednesday, a sedan with new self-driving features.&nbsp;The P5 is equipped with so-called Lidar to aid Xpeng’s driverless system called XPILOT.&nbsp;Xpeng is hoping to close to gap with Tesla as well as race ahead of other rivals such as Nio and Li Auto.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186838018","content_text":"(April 14) Electric vehicle stocks were down. Shares of Nio was down  6.62% to $33.13 and Nio was 3.14% lower.Xpeng Motors launched the P5 on Wednesday, a sedan with new self-driving features. The P5 is equipped with so-called Lidar to aid Xpeng’s driverless system called XPILOT. Xpeng is hoping to close to gap with Tesla as well as race ahead of other rivals such as Nio and Li Auto.","news_type":1,"symbols_score_info":{"NIO":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":67,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150977893,"gmtCreate":1624885513012,"gmtModify":1633947534227,"author":{"id":"3574151786459188","authorId":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574151786459188","authorIdStr":"3574151786459188"},"themes":[],"htmlText":"Omggggg","listText":"Omggggg","text":"Omggggg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150977893","repostId":"2146887989","repostType":4,"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}